The funding will be used to expedite the development of Synchron’s first platform product (Synchron SwitchTM BCI) as well as the launch of a pivotal clinical trial
Reliance Industries informed the bourses that its subsidiary Reliance Digital Health has signed definitive agreements with Synchron to acquire a 2.25 per cent stake (on a fully diluted basis) as part of its Series C financing round.
Synchron, an endovascular brain-computer interface (BCI) company, announced a $75 million Series C financing round led by ARCH Venture Partners that was oversubscribed. ARCH welcomes new investors Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X.
The funding will be used to expedite the development of Synchron’s first platform product (Synchron SwitchTM BCI) as well as the launch of a pivotal clinical trial, said Synchron.
The Series C funding brings the total funds raised since the company’s inception to $145 million.
